Therapeutic Response

ER positive status confers therapeutic sensitivity to Exemestane in patients with Invasive Breast Carcinoma.

Statements

Source and description
Exemestane Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved exemestane for reimbursement as a monotherapy treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in patients who are postmenopausal women.
Aromasin (exemestane) [summary of product characteristics]. HPRA. The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized exemestane for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive invasive early breast cancer (EBC) who have received 2 to 3 years of initial tamoxifen therapy.